CENTRE LEON BERARD;F. HOFFMANN-LA ROCHE AG;UNIVERSITE CLAUDE BERNARD-LYON 1;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.本發明係關於用於治療HBV感染(尤其慢性HBV感染)之FUBP1抑制劑。本發明尤其關於FUBP1抑制劑用於使cccDNA(諸如HBV cccDNA)去穩定化之用途。本發明亦關於核酸分子,諸如寡核苷酸,包括siRNA、shRNA及反義寡核苷酸,該等核酸分子與FUBP1互補且能夠減少FUBP1 mRNA。本發明亦包含醫藥組合物及其在治療及/或預防HBV感染中之用途。